Physician profile
Madilynn Perrigo
NPI 1619753803
$1,008.70
in general payments reported to CMS, 2019-2025
14 companies · $85.89 in 2025
The $85.89 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $387 · 2024: $536 · 2025: $85.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.64 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $148.05 | 2023 | Erleada |
| Boston Scientific Corporation | $146.75 | 2024 | Rezum Generator, Obtryx System - Curved |
| Pfizer INC. | $129.70 | 2024 | |
| Sumitomo Pharma America, INC. | $127.95 | 2023-2024 | Gemtesa |
| Teleflex LLC | $82.46 | 2024 | Urolift |
| Myriad Genetic Laboratories, INC. | $63.61 | 2024 | Prolaris |
| Endo USA, INC. | $53.93 | 2024-2025 | Xiaflex, Aveed |
| Blue Earth Diagnostics | $52.23 | 2023 | |
| Merck Sharp & Dohme LLC | $48.00 | 2024-2025 | Keytruda |
| Urogen Pharma, INC. | $46.91 | 2023 | Jelmyto |
| Endo Pharmaceuticals INC. | $42.98 | 2023-2024 | Aveed, Xiaflex |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Abbvie INC. | $17.62 | 2024 | |
| Halozyme INC | $13.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madilynn Perrigo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.